Table 4.
Associations of serum RBP4 with clinical outcomes in CHF patients
| Model | 1st quartile | 2nd quartile | 3rd quartile | 4th quartile |
|---|---|---|---|---|
| MACEs | ||||
| Crude model | 1 | 1.45 (1.10–1.90)* | 1.47 (1.29–1.68)* | 1.53 (1.40–1.66)* |
| Adjusted model | 1 | 1.14 (0.85–1.55) | 1.17 (0.99–1.38) | 1.39 (1.25–1.55)* |
| Cardiovascular mortality | ||||
| Crude model | 1 | 1.64 (1.41–1.91)* | 1.73 (1.36–2.19)* | 2.23 (1.38–3.60)* |
| Adjusted model | 1 | 1.19 (0.89–1.62) | 1.22 (0.91–1.63) | 1.33 (1.09–1.61)* |
| Rehospitalization | ||||
| Crude model | 1 | 1.25 (0.88–1.76) | 1.35 (1.15–1.60)* | 1.48 (1.34–1.64)* |
| Adjusted model | 1 | 1.01 (0.69–1.47) | 1.15 (0.95–1.41) | 1.39 (1.22–1.59)* |
CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiac event(s); RBP4, retinol‐binding protein 4.
The adjusted model included age, sex, BMI, ischaemic aetiology, hypertension, diabetes, smoking, NYHA functional class, LVEF, NT‐proBNP, eGFR, and medical treatments.